tirzepatide shortage fda update declares Mounjaro, Zepbound over The Impact of New FDA

PMCID: PMC7108996

1 Key results: Semaglutide 2.4 mg: -15.8% body weight loss Liraglutide 3 mg: -6.4% body weight loss Treatment difference: -9.4 percentage points in favour of semaglutide The proportion achieving clinically meaningful weight loss: Important note about Ozempic doses The STEP 8 trial used semaglutide 2.4 mg, which is the Wegovy dose for weight management

For melasma and hyperpigmentation specifically, consistency matters most

The circadian clock protein BMAL1 acts as a metabolic sensor in macrophages to control the production of pro IL-1b

Eating well, being more active and building healthier routines can improve your results and make them easier to maintain long term